NCT05103631View on ClinicalTrials.gov

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

June 17, 2021

Primary Completion Date

January 31, 2026

Study Completion Date

December 31, 2040

Conditions
Liver Cell CarcinomaSolid TumorWilms TumorMalignant Rhabdoid TumorYolk Sac TumorRhabdomyosarcomaLiposarcomaEmbryonal Sarcoma of the Liver
Interventions
GENETIC

CATCH T cells

"Four different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule. The following dose levels will be evaluated:~DL1: 3x10\^7/m2~DL2: 1x10\^8/m2~DL3: 3x10\^8/m2~DL4: 1x10\^9/m2~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."

Trial Locations (1)

77030

RECRUITING

Houston Methodist Hospital, Houston

All Listed Sponsors
collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

collaborator

The Methodist Hospital Research Institute

OTHER

lead

Baylor College of Medicine

OTHER